PRDM9 and cancer: Inhibitors targeting epigenetic factors have been explored for cancer therapies and have undergone clinical trials, including DNA methyltransferase 1 inhibitors, histone deacetylase inhibitors, and histone methyltransferase inhibitors [44–46].